Constitutive up-regulation of integrin-mediated adhesion of tumor-infiltrating lymphocytes to osteoblasts and bone marrow-derived stromal cells.
Tumor-reactive T cells, known as tumor-infiltrating lymphocyte(TIL)s are known to infiltrate various tumors. Although TILs exert cytotoxic activities against tumor cells, only a small percentage of tumors usually contain TILs that specifically react to tumor antigens. Because the exact role of these lymphocytes is unclear, we investigated the mechanisms of migration and adhesion of TILs to bone metastatic tumors, particularly to osteoblasts and bone marrow-derived stromal cell(BMSC)s. Histopathological examination showed that most TILs in secondary bone metastatic tumors (from primary tumors in the lung or breast) were found in the supporting tissue stroma between the bone and tumor mass. Cultured TILs (obtained from breast tumors) adhered spontaneously to osteoblasts and BMSCs (obtained from patients with osteoarthritis) without exogenous stimulation. Adhesion was further enhanced by chemokines macrophage inflammatory protein (MIP)-1alpha and MIP-1beta. TILs highly expressed activation antigens CD25 and CD69. A spontaneous activation of an integrin, lymphocyte function-associated antigen-1 (LFA-1), was also detected on TILs. TILs produced high concentrations of MIP-1alpha and MIP-1beta and spontaneous polymerization of cytoskeletal F-actin was observed in these cells. Adhesion of TILs to osteoblasts and BMSCs via LFA-1 and very late antigen-4 was associated with the production of osteoclastogen interleukin 6 by the latter cells. Our results indicate that integrins on TILs are activated in an autocrine manner by MIP-1alpha and MIP-1beta, and that treatment with the chemokines increases the binding of TILs on osteoblasts and stromal cells via a mechanism involving intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 as targets for the integrin. Our data also indicated that interactions between TILs and osteoblasts/stromal cells lead to the secretion by the latter of the osteoclastogenic cytokine interleukin 6.
Tanaka
Y
Y
First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu. tanaka@med.uoeh-u.ac.jp
Mine
S
S
Hanagiri
T
T
Hiraga
T
T
Morimoto
I
I
Figdor
C G
CG
van Kooyk
Y
Y
Ozawa
H
H
Nakamura
T
T
Yasumoto
K
K
Eto
S
S
D000199:Actins / Q000378:metabolism; D015703:Antigens, CD / Q000378:metabolism; D000945:Antigens, Differentiation, T-Lymphocyte / Q000378:metabolism; D001853:Bone Marrow / Q000276:immunology* / Q000378:metabolism; D001859:Bone Neoplasms / Q000276:immunology* / Q000556:secondary / Q000628:therapy; D002448:Cell Adhesion / Q000502:physiology; D002465:Cell Movement / Q000502:physiology; D054405:Chemokine CCL3; D054407:Chemokine CCL4; D005260:Female; D006801:Humans; D016219:Immunotherapy, Adoptive / Q000379:methods*; D016023:Integrins / Q000378:metabolism*; D018799:Intercellular Adhesion Molecule-1 / Q000378:metabolism; D015850:Interleukin-6 / Q000378:metabolism; D037181:Lectins, C-Type; D016169:Lymphocyte Function-Associated Antigen-1 / Q000378:metabolism; D016246:Lymphocytes, Tumor-Infiltrating / Q000378:metabolism / Q000502:physiology*; D019402:Macrophage Inflammatory Proteins / Q000378:metabolism; D010006:Osteoblasts / Q000276:immunology / Q000378:metabolism; D011108:Polymers; D015375:Receptors, Interleukin-2 / Q000378:metabolism; D017154:Stromal Cells / Q000378:metabolism; D015854:Up-Regulation; D019010:Vascular Cell Adhesion Molecule-1 / Q000378:metabolism; D000099192:CD69 Antigens
D000199:Actins; D015703:Antigens, CD; D000945:Antigens, Differentiation, T-Lymphocyte; D054405:Chemokine CCL3; D054407:Chemokine CCL4; D016023:Integrins; D018799:Intercellular Adhesion Molecule-1; D015850:Interleukin-6; D037181:Lectins, C-Type; D016169:Lymphocyte Function-Associated Antigen-1; D019402:Macrophage Inflammatory Proteins; D011108:Polymers; D015375:Receptors, Interleukin-2; D019010:Vascular Cell Adhesion Molecule-1; D000099192:CD69 Antigens